-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Repligen, Raises Price Target to $225

Benzinga·10/07/2026 15:20:40
Listen to the news
Barclays analyst Luke Sergott maintains Repligen (NASDAQ:RGEN) with a Overweight and raises the price target from $175 to $225.